In the normal breast, ERBB4 regulates epithelial differentiation and functions as a nuclear chaperone for signal transducer and activator of transcription (STAT) 5A, thereby stimulating milk-gene expression. In addition, ERBB4 functions as a proapoptotic protein, suppressing the growth of malignant cells. We hypothesize that these ERBB4 activities can be marshaled to suppress the growth of breast tumors. To this end, we have created an ERBB4 allele harboring an activating transmembrane mutation (ERBB4-CA) by substituting isoleucine 658 for glutamic acid. This base substitution forms a valine-glutamic acidglycine activation domain first identified in oncogenic ERBB2/HER2/Neu. Ectopic expression of ERBB4-CA in HEK293T cells resulted in a fivefold increase in receptor tyrosine phosphorylation. Functionally, ERBB4-CA exhibited higher levels of nuclear translocation than wild-type ERBB4, leading to significantly enhanced ERBB4-induced STAT5A simulation of the b-casein promoter. Activated ERBB4 has been demonstrated to induce cell killing of breast tumor cells. Significantly, ERBB4-CA potentiated the proapoptotic function of ERBB4 in each breast, prostate and ovarian cancer cell line tested. Untransformed cell lines were resistant to both ERBB4 and ERBB4-CA-mediated apoptosis underscoring the potential utility of active ERBB4 signaling for the therapeutic intervention of human cancer.
In the normal breast, ERBB4 regulates epithelial differentiation and functions as a nuclear chaperone for signal transducer and activator of transcription (STAT) 5A, thereby stimulating milk-gene expression. In addition, ERBB4 functions as a proapoptotic protein, suppressing the growth of malignant cells. We hypothesize that these ERBB4 activities can be marshaled to suppress the growth of breast tumors. To this end, we have created an ERBB4 allele harboring an activating transmembrane mutation (ERBB4-CA) by substituting isoleucine 658 for glutamic acid. This base substitution forms a valine-glutamic acidglycine activation domain first identified in oncogenic ERBB2/HER2/Neu. Ectopic expression of ERBB4-CA in HEK293T cells resulted in a fivefold increase in receptor tyrosine phosphorylation. Functionally, ERBB4-CA exhibited higher levels of nuclear translocation than wild-type ERBB4, leading to significantly enhanced ERBB4-induced STAT5A simulation of the b-casein promoter. Activated ERBB4 has been demonstrated to induce cell killing of breast tumor cells. Significantly, ERBB4-CA potentiated the proapoptotic function of ERBB4 in each breast, prostate and ovarian cancer cell line tested. Untransformed cell lines were resistant to both ERBB4 and ERBB4-CA-mediated apoptosis underscoring the potential utility of active ERBB4 signaling for the therapeutic intervention of human cancer. Keywords: EGFR-family; STAT5A; apoptosis; nuclear translocation; transactivation The receptor tyrosine kinase, ERBB4/HER4 (referred to here as ERBB4) is the final member of the epidermal growth factor receptor (EGFR) family to be discovered. In the normal breast, ERBB4 plays an indispensable role during pregnancy-induced epithelial differentiation and during the initiation of lactation at parturition (Jones et al., 2003; Long et al., 2003; Tidcombe et al., 2003) . Lactational milk-gene expression is impaired in response to ERBB4 ablation as a result of abolished signal transducer and activator of transcription (STAT) 5A nuclear translocation and signaling (Jones et al., 2003; Long et al., 2003; Tidcombe et al., 2003; Williams et al., 2004) . Interestingly, ERBB4 directly regulates milk-gene expression by functioning as a nuclear chaperone for STAT5A and ultimately associating with gene promoters containing STAT5A-binding sites (Williams et al., 2004) .
Despite an essential role in breast development and function, ERBB4 expression is lost during breast tumor progression (Srinivasan et al., 1998; Kew et al., 2000; Witton et al., 2003) . Moreover, and in contrast to the other EGFR-family members, namely EGFR, ERBB2 and ERBB3, ERBB4 expression in primary breast tumors inversely correlated with tumor progression and recurrences and ERBB4 expression is associated with overall improved patient prognosis (Kew et al., 2000; Barnes et al., 2005) . Interestingly, the ERBB4 intracellular domain (4ICD) functions as a cytosolic proapoptotic BCL-2 homology (BH) 3-only protein localizing to the mitochondria (Vidal et al., 2005; Naresh et al., 2006) . The cell-killing activity of 4ICD provides a mechanistic explanation for the selective loss of ERBB4 expression during breast tumor progression.
Based upon the recently identified functions for ERBB4 signaling, we predict that a constitutively active ERBB4 receptor would possess enhanced gene activation and cell-killing activities. Moreover, successful generation of a constitutively active ERBB4 receptor may provide a foundation for the development of augmented ERBB4 signaling as a therapeutic approach for the treatment of human cancer. To this end, we incorporated a base substitution within the transmembrane domain of ERBB4, that is, predicted to enhance receptor tyrosine phosphorylation. We then determined the signaling activity of the mutant ERBB4 receptor using several different biological and functional assays.
Generation of a constitutively active ERBB4 allele: Mutational activation of a member of the EGFR-family was first described for the rat ERBB2 homolog ERBB2/ Neu. A single base substitution of valine 664 for a glutamic acid within the transmembrane domain of the ERBB2/Neu receptor led to the formation of a transmembrane Val663-Glu664-Gly665 (VEG) domain which promoted an increase in receptor dimerization, as well as enhanced tyrosine kinase activity (Bargmann et al., 1986; Bargmann and Weinberg, 1988; Stern et al., 1988; Weiner et al., 1989) . Additional studies demonstrated that the transmembrane position of the VEG domain determined optimal ERBB2/Neu dimerization and transformation (Burke et al., 1997) . Incorporation of a similar transmembrane mutation led to constitutive activation of human ERBB2 (Segatto et al., 1988) and EGFR receptors (Miloso et al., 1995) (Figure 1b) . We reasoned that a similarly positioned VEG domain within the transmembrane domain of ERBB4 would result in a constitutively active receptor. We generated a VEG domain within the transmembrane region of the ERBB4 JMa/cyt1 isoform by substituting isoleucine 658 with glutamic acid (I658E) (Figure 1a and b). The ERBB4 I658E mutant harboring a carboxyl terminal Flag epitope tag was ectopically expressed in HEK293T cells and the levels of receptor tyrosine phosphorylation were determined in the presence or absence of the ERBB4 ligand heregulin b1 (HRG). Unstimulated constitutively active ERBB4 allele (ERBB4-CA) cDNA exhibited a fivefold increase in tyrosine phosphorylation when compared to wild-type ERBB4 (Figure 1c and d) , indicating that, as predicted, the I658E ERBB4 mutation generated a constitutively active ERBB4 receptor. HRG stimulation resulted in a slight increase in ERBB4-CA tyrosine phosphorylation. In contrast, HRG stimulated a significant increase in ERBB4 tyrosine phosphorylation. However, HRG failed to potentiate ERBB4 tyrosine phosphorylation to the level of ERBB4-CA in the absence of HRG. These results underscore the ability of a transmembrane VEG domain to potently activate the ERBB4 transmembrane receptor and our results implicate the transmembrane VEG domain as a common activation mechanism for EGFR-family members.
ERBB4-CA exhibits enhanced nuclear translocation and transcriptional coactivation: We have recently Figure 1 Insertion of a VEG domain within the ERBB4 transmembrane results in increased autophosphorylation. (a) Schematic of ERBB4 polypeptide indicating two amino-terminal cysteine-rich domains (cys1, cys2), position of the activating transmembrane (TM) I658E residue substitution and the ERBB4ICD harboring a nuclear localization signal (NLS) (Williams et al., 2004) and BH3 domain (Naresh et al., 2006) . (b) Alignment of transmembrane sequences of EGFR-family members human ERBB4, human ERBB2, rat ERBB2/Neu and human EGFR. VEG domains (MEG for EGFR) are boxed and base substitutions are underlined. The plasmids pERBB4-CA-EGFP and pERBB4-CA-Flag harboring a glutamic acid base substitution at isoleucine 658 (generating a transmembrane VEG domain) were generated in a SpeI/BclI fragment of pERBB4-EGFP and pERBB4-Flag (both plasmids harbor the ERBB4 JMa/cyt1 isoform) (Williams et al., 2004) by polymaerase chain reaction-mediated site-directed mutagenesis using the upstream primer 5 0 -GCTGATCCAGATCGGGAC (nt 1855-1873; GenBank no. NM00535), the downstream primer 5 0 -GGATGGTTGGGCTCA GAC (nt 2410-2393) and the mutation incorporating oligonucleotide primer pair 5 0 -GGAGTAGAGGGTGGGCTCTTCATTCTG (nt 1999-2025) and 5 0 -CCCACCCTCTACTCCAGCTGCAATCAG (nt 2013-1987) . The mutation was verified by sequencing. (c) Western blot analysis indicating increased autophosphorylation of ERBB4-CA. HEK293T cells were transfected with 2 mg of the indicated expression plasmid using Fugene6 (Roche Diagnostics, Indianapolis, IN, USA) exactly as described by the manufacturer. Two days post-transfection, cells were lysed in EBC-buffer and ERBB4 was immunoprecipitated (anti-ERBB4; Santa Cruz Biotechnology, Santa Cruz, CA, USA) from 1 mg of total lysate exactly as described elsewhere (Jones et al., 1999) . Western blot analysis was performed as described (Jones et al., 1999) using anti-ERBB4 (Santa Cruz) and anti-phospho-tyrosine (Santa Cruz) antibodies. (d) Western blot band density measurements were determined and recorded as arbitrary units using a ChemiImager 4000 Low Light Imaging System (Alpha Innotech Corporation, San Leandro, CA, USA). The data from three independent experiments was represented graphically as the mean and standard error of the P-tyr and ERBB4 band intensity ratio. demonstrated that ERBB4 processing by g-secretase and subsequent nuclear translocation of 4ICD contributes to gene expression by functioning as a nuclear chaperone for STAT5A (Williams et al., 2004; Vidal et al., 2005) . To determine whether ERBB4-CA enhances ERBB4 signaling activity, we compared the levels of ERBB4 and ERBB4-CA nuclear localization and transcriptional coactivation of STAT5A at a b-casein promoter fused to luciferase. ERBB4 and ERBB4-CA fused to EGFP were transfected into MCF-7B cells and mock stimulated or stimulated with HRG. Deconvolution microscopy revealed lower basal levels of nuclear ERBB4 (Figure 2a and e) when compared to ERBB4-CA (Figure 2c and e). Consistent with our previous observations (Williams et al., 2004) , HRG stimulation of ERBB4-transfected cells resulted in a modest but significant increased accumulation of EGFP label in transfected cell nuclei (Figure 2b and e) . The level of HRG stimulated ERBB4 nuclear translocation was significantly lower than mock stimulated ERBB4-CA (Figure 2e ). In concordance with the small impact of HRG on ERBB4-CA phosphorylation, HRG treatment of ERBB4-CA-transfected cells resulted in a slight insignificant increase in ERBB4-CA nuclear accumulation (Figure 2d and e) . The confocal microscopy quantitative analysis of ERBB4 nuclear localization was confirmed by Western blot analysis of ERBB4 and ERBB4-CAtransfected and fractionated MCF-7B cell lysates. Indeed, increased nuclear accumulation of 4ICD was observed in ERBB4-CA-transfected cells when compared to similarly treated ERBB4-transfected cells (Figure 2f ). Taken together, these results are consistent with the previous observation that ERBB4 nuclear translocation was proportional to the level of ERBB4 activation (Ni et al., 2001 ).
Figure 2 ERBB4-CA exhibits enhanced 4ICD nuclear translocation. The MCF-7B breast cancer cell line cultured on coverslips was transfected with 2 mg of (a, b) ERBB4-EGFP or (c, d) ERBB4-CA using Fugene6. At 2 days post-transfection cells were (a, c) mock stimulated or (b, d) stimulated with 50 ng/ml of heregulin b1 for 30 min at room temperature. Following stimulation, cells were fixed in 4% paraformaldehyde for 10 min, stained with 10 mM Hoechst reagent (Molecular Probes, Eugene, OR, USA) for 10 min, and mounted onto glass slides using Prolong Antifade Mounting Media (Molecular Probes). The slides were analysed on a Leica DMRXA automated upright epifluorescent microscope (Leica Microsystems, Bannockburn, IL, USA) equipped with a Â 63(NA 1.4) oilimmersion objective; a Sensicam QE CCD digital camera (Cooke Corporation, Auburn Hills, MI, USA); and filter sets optimized for EGFP (exciter HQ480/20, dichroic Q495LP, and emitter HQ510/20 m) and DAPI (exciter 360/40 Â , dichroic 400DCLP, and emitter GG420LP). (e) Quantitation of nuclear and cytoplasmic EGFP. A total of 20 cells from each treatment with equivalent levels of EGFP expression (ca. EGFP volume ¼ 1000 mm 3 ) were identified and the EGFP volume within each cellular compartment (nuclear and cytosolic) was determined exactly as described elsewhere (Williams et al., 2004) . Each bar represents the mean and s.e. nuclear (black) or cytosolic (white) EGFP volumes from three independent experiments. Single asterisks indicates sample significantly different from ERBB4 mock and double asterisks indicates sample significantly different from ERBB4 HRG. (f) MCF-7B cells were transfected with the indicated expression vectors as described above and at 2 days post-transfection cells were mock stimulated or stimulated with 50 ng/ml of HRG for 1 h. Nuclear extracts were prepared and probed by Western blot for 4ICD (anti-ERBB4) or histone H3 exactly as described elsewhere (Williams et al., 2004) .
We have recently demonstrated that ERBB4 induces STAT5A stimulation of gene expression (Williams et al., 2004; Clark et al., 2005) , which requires nuclear accumulation of ERBB4 (Williams et al., 2004) . By extension, we predict that ERBB4-CA would potentiate STAT5A transactivation activity. Consistent with our previous observations, cotransfection of ERBB4 and STAT5A resulted in a significant increase in the stimulation of the b-casein promoter fused to luciferase (Figure 3 ). ERBB4-CA, which exhibits increased nuclear accumulation, augmented STAT5A-stimulation of the b-casein promoter to levels significantly greater than ERBB4 (Figure 3) . These results indicate that the increase in autophosphorylation observed in the ERBB4-CA mutant leads to a functional increase in receptor downstream signaling.
ERBB4-CA exhibits enhanced apoptotic activity: In addition to a role as a transcriptional coactivator, we have demonstrated that proteolytic processing of ERBB4 results in mitochondrial accumulation of 4ICD and apoptosis of breast tumor cells (Vidal et al., 2005; Naresh et al., 2006) . To determine whether ERBB4-CA possesses enhanced cell-killing activity, we transfected untransformed and malignant human breast and prostate cancer cell lines and a human ovarian cancer cell line with pEGFPN3 (vector), ERBB4-EGFP or ERBB4-CA-EGFP. The percentage of morphologically apoptotic EGFP-positive cells was determined by counting cells with condensed Hoechst staining at 40 h post-transfection. ERBB4 and ERBB4-CA induced low, insignificant levels of apoptosis when transfected into the HME-TERT untransformed breast epithelial cell line as well as the untransformed prostate epithelial cell line PREC (Figure 4) . The level of apoptosis induced by ERBB4-CA was greater than ERBB4 in each malignant cell line tested and, with the exception of SKBr3 breast cancer cells, the differences were statistically significant (Figure 4) . The lack of ERBB4 or ERBB4-CA cellkilling when transfected into the untransformed cell lines HME-TERT and PREC supports our contention that ERBB4 signaling may be marshaled to suppress tumor growth while having little to no impact on normal tissue. Moreover, our data demonstrating ERBB4-and ERBB4-CA-induced apoptosis of prostate and ovarian cancer cells provide a mechanistic explanation for the growing body of clinical evidence indicating that, similar to breast cancer, loss of ERBB4 expression is a common feature of these diseases (Srinivasan et al., 1998; Yarden and Sliwkowski, 2001) .
Summary: In this communication we describe an ERBB4 allele harboring an activating transmembrane Cell lysates were prepared at 2 days post-transfection in Cell Culture Lysis Reagent (Promega, Madison, WI, USA) and a luciferase assay was performed exactly as described elsewhere (Williams et al., 2004) . All samples were prepared in duplicate and the results are represented as the mean plus s.e. from at least three independent experiments. Statistically significant differences between data sets were determined using the paired Student's t-test. Single asterisk indicating STATSA/ERBB4 were significantly different from STAT5A and double asterisks indicating STA-T5A/ERBB4-CA cotransfection were significantly different from STAT5A/ERBB4 (Po0.05).
Figure 4 ERBB4-CA exhibits enhanced apoptotic activity. Each cell line was transfected with 2 mg of ERBB4-EGFP, ERBB4-CA-EGFP, or the vector control pEGFPN3 using Fugene6. At 40 h post-transfection, the percentage of EGFP-positive apoptotic cells was determined. Approximately 300 EGFP-positive cells from each sample were counted. Each sample was prepared in duplicate and the entire experiment was repeated three times. Results are represented as the mean apoptotic cells plus standard error. Statistically significant differences between data sets were determined using the paired Student's t-test. Asterisks indicating ERBB4-CA were significantly different from ERBB4 (Po0.02).
VEG domain (ERBB4-CA). The VEG domain was first identified as the activating transmembrane mutation of Neu, the rat oncogenic form of ERBB2 (Bargmann et al., 1986; Bargmann and Weinberg, 1988; Stern et al., 1988; Weiner et al., 1989) . Our generation of ERBB4-CA through insertion of a VEG domain is in concordance with similar mutations resulting in constitutive activation of human EGFR (Miloso et al., 1995) and ERBB2 (Segatto et al., 1988) , implying that the VEG domain represents an EGFR-family activation motif.
Functionally, ERBB4-CA exhibited enhanced nuclear translocation and significantly potentiated STAT5A stimulation of gene expression, indicating that ERBB4-CA not only harbors increased tyrosine autophosphorylation, but also exhibits enhanced ERBB4 downstream signaling activity. In addition, ERBB4-CA-induced cell killing, of each tumor cell line tested, at levels significantly greater than wild-type ERBB4. Interestingly, untransformed breast and prostate cell lines were resistant to both ERBB4 and ERBB4-CA-induced apoptosis. We have previously demonstrated that ERBB4 transcriptional coactivator and cell-killing activities both require proteolytic processing of ERBB4 at the cell surface to release 4ICD (Williams et al., 2004; Vidal et al., 2005; Naresh et al., 2006) . Enhanced 4ICD signaling observed in ERBB4-CA-transfected cells may be explained by augmented proteolytic processing of ERBB4-CA at the cell surface resulting in an increase in membrane release of 4ICD. We are currently investigating the influence of ERBB4-CA on the recruitment of membrane-associated proteolytic-enzyme complexes and subsequent processing of the holoreceptor.
In conclusion, the apparent resistance of untransformed cells to ERBB4-induced apoptosis supports a tumor suppressor function for ERBB4 and implies that the enhanced cell-killing activity associated with an activated ERBB4 receptor can be marshaled as a therapeutic approach to specifically target human cancer cells. We propose that selective activation of ERBB4, for example using a dimerizing antibody, may provide a therapeutic approach for the release of 4ICD cell-killing activity in human cancer.
